Barrington Research initiated coverage on PaySign with a new price target
$PAYS
Business Services
Consumer Discretionary
Barrington Research initiated coverage of PaySign with a rating of Mkt Perform and set a new price target of $4.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | $6.00 | Buy | Lake Street |
| 3/30/2022 | $4.00 | Mkt Perform | Barrington Research |
| 3/24/2022 | Buy → Neutral | Ladenburg Thalmann | |
| 8/20/2021 | $3.50 | Neutral → Buy | DA Davidson |
| 8/19/2021 | Neutral → Buy | DA Davidson | |
| 8/12/2021 | $3.50 → $3.75 | Neutral → Buy | Ladenburg Thalmann |
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability solutions, financial technology products, and integrated payment processing services, today announced the successful transition of 123 out of 132 newly awarded plasma donation centers. The remaining nine centers are on track to go live in the third quarter of 2025. The onboarding of 123 centers was completed in just one week – significantly ahead of schedule – demonstrating Paysign's operational agility, platform scalability and executional discipline. "Successfully transitioning this volume of centers in a single week is a testament to the strength of our platform, the rigor of our processes and the exceptional c
The Additions Significantly Increase the Company's U.S. Plasma Market Share Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability solutions, financial technology products, and integrated payment processing services, today announced that it has been awarded 132 established plasma donation centers through an expansion of its long-standing relationship with a major plasma collection company. Transition of the centers from the incumbent provider is underway, with 123 centers expected to be live by the end of the second quarter of 2025 and the remaining nine slated for transition during the third quarter of 2025. "The addition of these centers underscores the strengths of
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced its CFO, Jeff Baker, will be attending and presenting at the MicroCap Rodeo Spring Conference in New York City on Wednesday, June 4, 2025. The presentation will be at 3:00 p.m. Eastern time on Wednesday, June 4, and will be webcast live. Interested parties can register to watch the virtual presentation. Management will also be available for one-on-one meetings with approved investors. Investors interested in attending may visit the event website for more information and to pre-register. Abo
8-K - Paysign, Inc. (0001496443) (Filer)
8-K - Paysign, Inc. (0001496443) (Filer)
10-Q - Paysign, Inc. (0001496443) (Filer)
Lake Street initiated coverage of PaySign with a rating of Buy and set a new price target of $6.00
Barrington Research initiated coverage of PaySign with a rating of Mkt Perform and set a new price target of $4.00
Ladenburg Thalmann downgraded PaySign from Buy to Neutral
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
Paysign Strengthens Leadership in Technology for Plasma and Pharmaceutical Industries Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability solutions, financial technology products, and integrated payment processing services, today announced that it has acquired the assets of Gamma Innovation LLC (Gamma), significantly enhancing Paysign's capabilities in plasma donor and pharmaceutical patient engagement technologies. As part of this strategic acquisition, Paysign has appointed Michael Ngo, former Managing Member of Gamma, as its Chief Innovation Officer. "This acquisition represents an exciting milestone for Paysign as we accelerate our growth strategy and expand our
First quarter 2025 total revenues of $18.60 million, up 41.0% from first quarter 2024 First quarter 2025 net income of $2.59 million, or diluted earnings per share of $0.05, versus net income of $309 thousand, or diluted earnings per share of $0.01, for first quarter 2024 First quarter 2025 Adjusted EBITDA of $4.96 million, up 193.3% from $1.69 million a year ago, while diluted Adjusted EBITDA per share was $0.09 versus $0.03 for first quarter 20241 Total plasma center count increased by four net centers during first quarter 2025, exiting the quarter with 484 centers; revenue per plasma center decreased to $6,517 compared to $7,414 for the same period last year; year-over-year plasma
For the Full-Year Full-year 2024 total revenues of $58.38 million, up 23.5% from full-year 2023 Full-year 2024 net income of $3.82 million, or diluted earnings per share of $0.07, versus net income of $6.46 million, or diluted earnings per share of $0.12 for full-year 2023 Full-year 2024 Adjusted EBITDA of $9.62 million, up 43.3% from $6.71 million a year ago, while diluted Adjusted EBITDA per share was $0.17 versus $0.12 for full-year 20231 Total plasma center count increased by 16 during 2024, exiting the year with 480 centers, contributing to a 4.6% increase in plasma revenue versus the same period last year Added 33 net patient affordability programs during 2024, exiting the y
Second quarter 2024 total revenues of $14.33 million, up 29.8% from second quarter 2023 Second quarter 2024 net income of $697 thousand, or diluted earnings per share of $0.01, versus net loss of $104 thousand, or diluted earnings per share of $(0.00) for second quarter 2023 Second quarter 2024 Adjusted EBITDA of $2.24 million, up 95.8% from $1.14 million for second quarter 2023, while diluted Adjusted EBITDA per share was $0.04 versus $0.02 for second quarter 20231 Total plasma center count increased by eight net new centers during second quarter 2024, exiting the quarter with 477 centers, contributing to a 12.6% increase in plasma revenue versus the same period last year Adde
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)